1 in 6 people in NYC (1.4 million) rely on daily emergency food. (Source: Robin Hood Foundation)

News

  • Celebrating the 10th Anniversary of the Louis V. Gerstner, Jr. Scholars Program at Columbia University
    July 25, 2018

    The Louis V. Gerstner, Jr. Scholars Program celebrated its 10th anniversary on June 20th at the Columbia University Irving Medical Center (CUIMC). To date, 44 promising young physicians have been awarded over $7 million to promote the next generation of physician-scientists in medicine and research. Each scholar receives two years of early-stage funding that is essential to generate sufficient data to apply for larger government grants. This investment by the Foundation has been leveraged to secure nearly $100 million in additional funding from the NIH. Gerstner Scholars’ research interests are broad and include cardiovascular disease, respiratory illness, substance abuse disorders, and pre-term labor to name a few. The ultimate goal of each award is to bridge the gap between scientific research in the lab to new therapies for patients. For more details on the Gerstner Scholars Program and its awardees, please see the attached report.

    Gerstner Scholars Program Report
  • Fourteen of 15 into Stanford early: Eye-popping admission stats for low-income advising program
    April 2, 2018

    Stanford University is the most selective in the country for undergraduate admissions, drawing more than 40,000 applicants a year and turning away 19 for every one it accepts. But a select cadre of high school seniors is getting into the private university in Silicon Valley at a much higher rate. They are scholars in a nonprofit advising program called Leadership Enterprise for a Diverse America, which helps students from low-income families apply to college. Fifteen of them applied to Stanford last fall for early admission to the class entering in 2018. In December, the program reports, 14 got in.

    Read more at washingtonpost.com
  • ‘Liquid biopsy’ can help predict outcomes in metastatic triple-negative breast cancer
    March 6, 2018

    A clinically relevant "liquid biopsy" test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer (TNBC). Although TNBC represents just 10-15 percent of all breast cancer diagnoses, the disease is responsible for 35 percent of all breast cancer-related deaths. While significant advances in understanding the genomic drivers of primary TNBC have been made in the past decade, relatively little is known about metastatic disease because surgical tumor biopsies are rarely obtained from these patients. Funding for the study was provided by the Gerstner Family Foundation, Susan G. Komen for the Cure, The Pink Agenda, Breast Cancer Research Foundation, V Foundation for Cancer Research and National Cancer Institute.

    Read more at eurekalert.org